Back to Journals » Psoriasis: Targets and Therapy » Volume 11

Off-Label Treatments for Pediatric Psoriasis: Lessons for the Clinic

Authors Haulrig MB, Zachariae C, Skov L

Received 8 December 2020

Accepted for publication 14 January 2021

Published 11 February 2021 Volume 2021:11 Pages 1—20

DOI https://doi.org/10.2147/PTT.S268462

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 2

Editor who approved publication: Prof. Dr. Uwe Wollina


Morten B Haulrig,1 Claus Zachariae,1,2 Lone Skov1,2

1Department of Dermatology and Allergy, Herlev and Gentofte Hospital, University of Copenhagen, Hellerup, DK-2900, Denmark; 2Copenhagen Research Group for Inflammatory Skin (CORGIS), Hellerup, Denmark

Correspondence: Morten B Haulrig
Department of Dermatology and Allergy, Herlev and Gentofte Hospital, Gentofte Hospitalsvej 15, DK-2900, Denmark
Tel +45 38 67 31 32
Fax +45 38 67 71 18
Email Morten.bahrt.haulrig@regionh.dk

Abstract: Psoriasis is a chronic inflammatory skin disease that affects up to 1.2% of children and adolescents. The treatment options for childhood psoriasis are often based on the same principles as in adults. However, most data on safety and efficacy derive from adult studies, and only a few of the frequently used treatments have achieved approval for use in children. The aim of this study was to review the current literature on off-label treatments for psoriasis in children and adolescents. We searched PubMed and identified 50 studies on off-label treatments. Of these, 23 studies were clinical trials (four randomized). There are only a small number of available studies on off-label treatments for children and adolescents with psoriasis, and many of these are retrospective reviews with few participants. Despite the current lack of studies, we still recommend the use of unapproved treatments since we have clinical experience with treatments such as topical corticosteroids, vitamin D analogs, and methotrexate that have shown promising effects. Regular clinical trials are needed to investigate the safety and efficacy of unapproved treatments. Due to The Pediatric Investigation Plans issued by The European Union, new drugs developed by pharmaceutical companies are required to undergo clinical trials in a pediatric population to get their application for marketing authorization processed. This will hopefully lead to much more data on the efficacy and safety of the new treatments, including treatments for children and adolescents with psoriasis.

Keywords: psoriasis, unapproved treatment, childhood, adolescents

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]